Silverman, Daniel, M.D., Ph.D.
  • Clinical Professor, Biomedical Physics IDP and Molecular & Medical Pharmacology at UCLA

  • Member, ACCESS Program: Dept. of Molecular & Medical Pharmacology

Silverman, Daniel, M.D., Ph.D.


Medical Center, MC694215
Los Angeles, CA 90095
Tel: (310) 825-4257
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Neuronuclear Imaging, Biochemistry, Molecular and Medical Pharmacology.



Daniel H. Silverman, M.D., Ph.D., is Head of the Neuronuclear Imaging Section of the Ahmanson Translational Imaging Division at UCLA Medical Center, on the Executive Committee of the UCLA Alzheimer's Disease Research Center, and a Professor in the Department of Molecular and Medical Pharmacology, University of California, Los Angeles. He obtained his Ph.D. in Biological Chemistry at Harvard University, and postdoctoral research training in Biochemistry and Molecular Pharmacology at Harvard Medical School. He obtained his M.D. from The Ohio State University College of Medicine, subsequently completed post-M.D. training at UCLA, and then obtained certification from both the American Board of Internal Medicine and the American Board of Nuclear Medicine.


Publications (selected peer-reviewed publications)

  • Raji CA, Eyre H, Wei SH, Bredesen DE, Moylan S, Law M, Small G, Thompson PM, Friedlander RM, Silverman DH, Baune BT, Hoang TA, Salamon N, Toga AW, Vernooij MW. Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline. AJNR Am J Neuroradiol 2015, June 4. [Epub ahead of print]
  • Pilhatsch M, Schlagenhauf F, Silverman D, Berman S, London ED, Martinez D, Whybrow PC, Bauer M. Antibodies in autoimmune thyroiditis affect glucose metabolism of anterior cingulate. Brain Behav Immun 2014; 37:73-77.
  • Ganz PA, Petersen L, Castellon SA, Bower JE, Silverman DH, Cole SW, Irwin MR, Belin TR. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol 2014;32:3559-3567.
  • Rasgon NL, Kenna HA, Wroolie TE, Williams KE, DeMuth BN, Silverman DH. Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy. Psychiatry Res 2014;223(1):28-36.
  • Rasgon NL, Geist CL, Kenna HA, Wroolie TE, Williams KE, Silverman DH. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PLoS One 2014;e89095.
  • Hurria A, Patel SK, Mortimer J, Luu T, Somlo G, Katheria V, Ramani R, Hansen K, Feng T, Chuang C, Geist CL, Silverman DH. The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clin Breast Cancer 2014;14:132-140.
  • Yamane T, Ikari Y, Nishio T, Ishii K, Ishii K, Kato T, Ito K, Silverman DH, Senda M, Asada T, Arai H, Sugishita M, Iwatsubo T; J-ADNI Study Group. Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation. AJNR Am J Neuroradiol 2014;35:244-249.
  • Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DH, Geist C, Breen EC, Irwin MR, Cole SW. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 2013;30 Suppl:S99-108.
  • Pomykala KL, de Ruiter MB, Deprez S, McDonald BC, Silverman DH. Integrating imaging findings in evaluating the post-chemotherapy brain. Brain Imaging Behav 2013;7:436-452.
  • Saykin AJ, de Ruiter MB, McDonald BC, Deprez S, Silverman DH. Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research. Brain Imaging Behav 2013;7:363-373.
  • Pomykala KL, Ganz PA, Bower JE, Kwan L, Castellon SA, Mallam S, Cheng I, Ahn R, Breen EC, Irwin MR, Silverman DH. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav 2013;7:511-523.
  • Chew J, Silverman DHS. FDG-PET in early AD diagnosis. The Medical clinics of North America 2013;97(3):485-94.
  • Smid LM, Kepe V, Vinters HV, Bresjanac M, Toyokuni T, Satyamurthy N, Wong K-P, Huang S-C, Silverman DHS, Miller K, Small GW, Barrio JR. Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging. Journal of Alzheimer's disease : JAD 2013;36(2):261-274.
  • Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DHS, Cole SW, Irwin MR, Ancoli-Israel S, Belin TR. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. Journal of the National Cancer Institute. 2013;105(11):791-801.
  • Ercoli LM, Small GW, Siddarth P, Kepe V, Huang SC, Miller KJ, Lavretsky H, Bookheimer SY, Barrio JR, Silverman DH. Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging. Int J Geriatr Psychiatry 2012;27:1017-1027.
  • Torosyan N, Silverman DHS. Neuronuclear imaging in the evaluation of dementia and mild decline in cognition. Seminars in nuclear medicine 2012;42(6):415-422.
  • Pomykala KL, Silverman DHS, Geist CL, Voege P, Siddarth P, Nazarian N, St Cyr NM, Khalsa DS, Lavretsky H. A pilot study of the effects of meditation on regional brain metabolism in distressed dementia caregivers. Aging health 2012;8(5):509-516.
  • Bauer M, Silverman DH, Schlagenhauf F, London ED, Geist CL, van Herle K, Rasgon N, Martinez D, Miller K, van Herle A, Berman SM, Phelps ME, Whybrow PC. Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy. J Clin Endocrinol Metab 2009;94:2922-2929.
  • Buchert R, Santer R, Brenner W, Apostolova L, Mester J, Clausen M, Silverman DH. Computer simulations suggest that acute correction of hyperglycaemia with an insulin bolus protocol might be useful in brain FDG PET. Nuklearmedizin 2009;48:44-54.
  • Seibyl JP, Chen W, and Silverman DHS. 3,4-Dihydroxy-6- [F-18] -Fluoro-L-Phenylalanine Positron Emission Tomography in Patients with Central Motor Disorders and in Evaluation of Brain and Other Tumors. Seminars in Nuclear Medicine 2007;37:440-450.
  • Silverman DHS, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5 to 10 years after chemotherapy. Breast Cancer Res Treat 2007;103:303-311.
  • Kesner AL, Hsueh W-A, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DHS. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast xenografts. J Nucl Med 2007;48:2021-2027.
  • Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation with 18F-FLT PET. J Clin Oncol 2007;25:4714-4721.
  • Silverman DHS and Thompson PM. Structural and functional neuroimaging: focusing on mild cognitive impairment. Appl Neurol 2006;2:10-22.
  • Chen W, Silverman DHS, DelaloyeS, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy. J Nucl Med 2006;47:904-911.
  • Top